Skip to main content

Personalis, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

PSNL$15.95+1.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 9B. Other Information

Trading Arrangements

During the last fiscal quarter, certain of our officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted written plans for the sale of our securities as set forth in the table below.

Type of Trading Arrangement
Name and Position · Action · Adoption Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares of Common Stock to be Sold · Expiration Date
Christopher Hall, President & CEOAdoptionDecember 17, 2025X400,000December 31, 2026
Richard Chen, EVP, R&D, Chief Medical OfficerAdoptionDecember 23, 2025X900,000March 22, 2027
  • Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.

**Non-Rule 10b5-1 trading arrangement as defined in Item 408(c) of Regulation S-K under the Exchange Act.

Amended and Restated Bylaws

On February 24, 2026, our board of directors amended and restated the Company’s Amended and Restated Bylaws (the “Amended Bylaws”), effective immediately. Among other changes, the Amended Bylaws:

Modernize the stockholder proposal procedures and disclosure requirements set forth in Section 5 of the Amended Bylaws, including, without limitation, by adding certain requirements for stockholder nominated directors to furnish information supporting their eligibility to serve, limiting the number of nominees a stockholder may nominate for election, limiting the need to provide information about the other stockholders supporting the proposal to those who are financially supporting such proposal, adding additional disclosure requirements to disclose in a director nomination proposal notice relating to certain extrinsic arrangements and requiring stockholder (or a qualified representative of the stockholder) appearance at the annual or special meeting of stockholders of the Company to present a nomination or proposed business advanced by such stockholder;

Clarify that certain updates to a previously submitted stockholder proposal, including, without limitation, change or addition of nominees, matters, business and/or resolutions to be brought before the meeting, will not be permitted as updates and will instead constitute a new proposal and be subject to the stockholder proposal procedures and disclosure requirements set forth in Section 5 of the Amended Bylaws;

Simplify the description of the voting standards for the election of directors and other proposals at stockholder meetings in Section 8 of the Amended Bylaws;

Conform the notice provisions throughout the Amended Bylaws to the requirements of Section 232 of the General Corporation Law of the State of Delaware (the “DGCL”); and

Conform Section 12 of the Amended Bylaws concerning the list of stockholders in connection with stockholder meetings with the requirements of Section 219 of the DGCL.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended Bylaws, which are filed as Exhibit 3.2 to this Annual Report on Form 10-K.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.